Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000014758
Abstract: Abstract Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily treated patients should be assessed. Here, we evaluated the efficacy of paclitaxel… read more here.
Keywords: small cell; heavily treated; refractory small; paclitaxel ... See more keywords